User menu

Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.

Bibliographic reference Dessilly, Géraldine ; Panin, Nadtha ; Elens, Laure ; Haufroid, Vincent ; Demoulin, Jean-Baptiste. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.. In: Scientific Reports, Vol. 6, p. 29559 [1-9] (2016)
Permanent URL http://hdl.handle.net/2078.1/183376
  1. Medves Sandrine, Demoulin Jean-Baptiste, Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies, 10.1111/j.1582-4934.2011.01415.x
  2. Frankfurt O., Licht J. D., Ponatinib--A Step Forward in Overcoming Resistance in Chronic Myeloid Leukemia, 10.1158/1078-0432.ccr-13-0258
  3. DeRemer David L., Ustun Celalettin, Natarajan Kavita, Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia, 10.1016/j.clinthera.2008.11.014
  4. Tothova, E. et al. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha. Neoplasma 52, 63–67 (2005).
  5. An Xin, Tiwari Amit K., Sun Yibo, Ding Pei-Rong, Ashby Charles R., Chen Zhe-Sheng, BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review, 10.1016/j.leukres.2010.04.016
  6. Goldman John M., Melo Junia V., Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment, 10.1056/nejmra020777
  7. Stegmeier F, Warmuth M, Sellers W R, Dorsch M, Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib, 10.1038/clpt.2009.297
  8. Kantarjian Hagop M., Talpaz Moshe, Giles Francis, O'Brien Susan, Cortes Jorge, New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance, 10.7326/0003-4819-145-12-200612190-00008
  9. Balabanov Stefan, Braig Melanie, Brümmendorf Tim H., Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia, 10.1016/j.ddtec.2014.03.003
  10. Bixby D., Talpaz M., Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance, 10.1182/asheducation-2009.1.461
  11. Vasiliou Vasilis, Vasiliou Konstandinos, Nebert Daniel W, Human ATP-binding cassette (ABC) transporter family, 10.1186/1479-7364-3-3-281
  12. Ueda K., Cardarelli C., Gottesman M. M., Pastan I., Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine., 10.1073/pnas.84.9.3004
  13. Mahon F.-X., MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models, 10.1182/blood.v101.6.2368
  14. Mahon F.-X., Hayette S., Lagarde V., Belloc F., Turcq B., Nicolini F., Belanger C., Manley P. W., Leroy C., Etienne G., Roche S., Pasquet J.-M., Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression, 10.1158/0008-5472.can-08-1008
  15. Gromicho Marta, Dinis Joana, Magalhães Marta, Fernandes Alexandra R., Tavares Purificação, Laires António, Rueff José, Rodrigues António Sebastião, Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1, 10.3109/10428194.2011.584005
  16. Cascorbi I, Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects, 10.1067/mcp.2001.114164
  17. Schwab Matthias, Eichelbaum Michel, Fromm Martin F., GENETICPOLYMORPHISMS OF THEHUMANMDR1DRUGTRANSPORTER, 10.1146/annurev.pharmtox.43.100901.140233
  18. LI Yan-Hong, WANG Yong-Hua, LI Yan, YANG Ling, MDR1 Gene Polymorphisms and Clinical Relevance, 10.1016/s0379-4172(06)60027-9
  19. Haufroid Vincent, Genetic Polymorphisms of ATP-Binding Cassette Transporters ABCB1 and ABCC2 and their Impact on Drug Disposition, 10.2174/138945011795378487
  20. Dulucq S., Bouchet S., Turcq B., Lippert E., Etienne G., Reiffers J., Molimard M., Krajinovic M., Mahon F.-X., Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia, 10.1182/blood-2008-03-147744
  21. Au Anthony, Aziz Baba Abdul, Goh Ai Sim, Wahid Fadilah S. Abdul, Teh Alan, Rosline Hassan, Ankathil Ravindran, Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients, 10.1016/j.biopha.2014.01.009
  22. Zu Bailing, Li Yajuan, Wang Xin, He Dali, Huang Zhenglan, Feng Wenli, MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis, 10.2217/pgs.13.222
  23. Zheng Q, Wu H, Yu Q, Kim D H (Dennis), Lipton J H, Angelini S, Soverini S, Vivona D, Takahashi N, Cao J, ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis, 10.1038/tpj.2014.54
  24. Dickens David, Owen Andrew, Alfirevic Ana, Pirmohamed Munir, ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein : , 10.1097/fpc.0b013e328360d10c
  25. Skoglund Karin, Boiso Moreno Samuel, Baytar Maria, Jönsson Jan Ingvar, Gréen Henrik, ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro, 10.2147/pgpm.s45522
  26. Dessilly Géraldine, Elens Laure, Panin Nadtha, Capron Arnaud, Decottignies Anabelle, Demoulin Jean-Baptiste, Haufroid Vincent, ABCB1 1199G>A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines, 10.1371/journal.pone.0091555
  27. Elens Laure, Tyteca Donatienne, Panin Nadtha, Courtoy Pierre, Lison Dominique, Demoulin Jean-Baptiste, Haufroid Vincent, Functional defect caused by the 4544G>A SNP in ABCC2 : potential impact for drug cellular disposition, 10.1097/fpc.0b013e32834d672b
  28. Dohse M., Scharenberg C., Shukla S., Robey R. W., Volkmann T., Deeken J. F., Brendel C., Ambudkar S. V., Neubauer A., Bates S. E., Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib, 10.1124/dmd.109.031302
  29. Hegedűs C, Özvegy-Laczka C, Apáti Á, Magócsi M, Német K, Őrfi L, Kéri G, Katona M, Takáts Z, Váradi A, Szakács G, Sarkadi B, Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties : Interaction of Bcr-Abl inhibitors and MDR-ABC proteins, 10.1111/j.1476-5381.2009.00383.x
  30. Sen R., Natarajan K., Bhullar J., Shukla S., Fang H.-B., Cai L., Chen Z.-S., Ambudkar S. V., Baer M. R., The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2, 10.1158/1535-7163.mct-12-0302
  31. Fung, K. L. et al. MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer. Cancer research, doi: 10.1158/0008-5472.CAN-13-2064 (2014).
  32. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlägel U, von Bonin M, Pursche S, Bergemann T, Ehninger G, Schleyer E, P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate, 10.1038/sj.leu.2403257
  33. Shukla S, Sauna Z E, Ambudkar S V, Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2, 10.1038/sj.leu.2404897
  34. Shukla Suneet, Chen Zhe-Sheng, Ambudkar Suresh V., Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance, 10.1016/j.drup.2012.01.005
  35. Gurney H, Wong M, Balleine R L, Rivory L P, McLachlan A J, Hoskins J M, Wilcken N, Clarke C L, Mann G J, Collins M, Delforce S-E, Lynch K, Schran H, Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype, 10.1038/sj.clpt.6100201
  36. Kimchi-Sarfaty C., Oh J. M., Kim I.-W., Sauna Z. E., Calcagno A. M., Ambudkar S. V., Gottesman M. M., A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity, 10.1126/science.1135308
  37. Fung King Leung, Pan James, Ohnuma Shinobu, Lund Paul E., Pixley Jessica N., Kimchi-Sarfaty Chava, Ambudkar Suresh V., Gottesman Michael M., MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer , 10.1158/0008-5472.can-13-2064
  38. Parmley Joanna L., Hurst Laurence D., How do synonymous mutations affect fitness?, 10.1002/bies.20592
  39. Velghe A I, Van Cauwenberghe S, Polyansky A A, Chand D, Montano-Almendras C P, Charni S, Hallberg B, Essaghir A, Demoulin J-B, PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations, 10.1038/onc.2013.218